1
Report
Report on savings on generic and biosimilar drugs in the US.
In its new annual edition, the US Off-Patent Drug Manufacturers Association offers a new estimate of the savings derived from the commercialization of US generic and biosimilar medicines in 2022. Regarding biosimilars , estimated savings of more than $23Bn and 694 million total days of patient treatment have been generated since its entry into the North American market in 2015.
Association for Accessible Medicines
2
Article
The lack of promotion of biosimilars prevents savings of 431 million in pharmaceutical spending in Spain
Article from the newspaper Público that offers a review of biosimilars in Spain and in which BioSim has participated, offering some data of interest such as savings generated by biosimilars in the SNS (more than 2.800 million euros between 2009 and 2019). Among the main causes of slower adoption than would have been desired, due to the loss of savings it entails, BioSim highlighted the lack of incentives and training for professionals who would generate confidence at the beginning of the entry of biosimilars into the Spanish pharmaceutical market. .
Public Journal
3
ADIEX
Biosimilars in psoriasis
Third video within the 2nd season of the YouTube channel of video advice on “Biosimilars and Pharmacy”. In this case, the biosimilars used in psoriasis are addressed: adalimumab, etanercept and infliximab. The indications, routes of administration and different devices currently available for patients with this chronic inflammatory pathology are described.
CGCOF, Medicine Television and BioSim
https://www.youtube.com/watch?v=h7o0ZYHeO9U
4
News
The European Commission grants marketing authorization to three new biosimilars
Throughout the month of September, the first biosimilars of natalizumab, aflibercept and tocilizumab have received their corresponding marketing authorization from the European Commission. The three medicines received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at its meeting last July and now have the approval of Europe to be marketed in all Member States. In BioSim's tweet you can access the corresponding links of the three authorizations from the European Commission.
biosim
https://twitter.com/BioSim_es/status/1707717398252359815
5
Report
Biosimilars Market Review 2023
The Medicines for Europe Biosimilars Market Access Committee has conducted a 2023 biosimilars market review on biosimilar medicines policy across Europe (28 countries).
Highlights from this review illustrate both key challenges and recommendations on how to improve specific policy interventions (e.g. pricing and reimbursement, procurement, prescribing and dispensing) to improve the use of biosimilar medicines and competition in the market. biological market in Europe.